Click here to close now.




















Welcome!

News Feed Item

Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

NEW YORK, Jan. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

http://www.reportlinker.com/p01083061/Contrast-Media/Contrast-Agents-Market-By-Product-Iodinated-Gadolinium--Barium-By-Technique-X-ray-CT-MRI-Cath-Lab--Ultrasound--By-Application-Radiology-Interventional-Radiology--Interventional-Cardiology---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Contrast agents have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential drivers in the widespread use of contrast agents in the future.

The global contrast media market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global contrast media market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

The global contrast media market, though fairly mature at present (2012), still shows potential to grow over the next five years. It is propelled by the increasing demand for diagnostic imaging and image guided surgical procedures, technological advances in diagnostic imaging and the ever-increasing incidence rates of cancer and cardiac disorders. However, a few pivotal factors affecting the growth of this market are major economies of the world undergoing healthcare reforms, thereby affecting contrast media sales and the economic slowdown restricting the overall growth of this market.

The U.S. represents the largest contrast media market worldwide, followed by Europe and Japan. However, the economic slowdown has augmented opportunities for emerging markets like India and China to strengthen their position in the global arena. Advances in medical technology coupled with huge foreign investments from developed nations, allows these emerging markets to compete with global market leaders in this segment. Investment firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe, since the U.S. is on the brink of embracing healthcare reforms and major economies in Europe are still recovering from huge financial deficits.

The global marketplace is highly competitive, with several small players specific to a particular geography challenging major ones. Owing to the recession and the emerging opportunities in developing countries, many small companies have similar product offerings at competitive prices. Some of the major players profiled in this report are GE Healthcare (U.K.), Bracco Diagnostic, Inc. (Italy), Bayer Healthcare Pharmaceuticals (Germany), Covidien (Ireland) and Guerbet Group (France).

The scope of the report spans the global contrast media market which comprises:

 

Global Contrast Media Market, by Product

Barium-based contrast media

Iodinated contrast media

Low-osmolar contrast media (LOCM)

High-osmolar contrast media (HOCM)

Gadolinium-based contrast media

Global Contrast Media Market, by Route of Administration

 

Oral

Injection

Intravenous (I.V.)

Intra-arterial (I.A.)

Rectal

Urethral

Global Contrast Media Market, by Medical Procedure

 

X-ray

Computed tomography (CT)

Magnetic resonance imaging (MRI)

Ultrasound

Catheterization laboratory (cath lab)

Global Contrast Media Market, by Indication

 

Cardiovascular disorders

Neurological disorders

Gastrointestinal disorders

Respiratory diseases

Musculoskeletal anomalies

Nephrological disorders

Oncology (tumor detection)

Global Contrast Media Market, by Application

 

Radiology

Interventional radiology

Interventional cardiology

Contrast Media Market, by Geography

 

North America

U.S.

Canada

Europe

United Kingdom (U.K.)

Germany

France

Italy

Spain

Scandinavian countries (Sweden, Denmark, Finland, and Norway)

Rest of Europe

Asia-Pacific (APAC)

Japan

China

India

Rest of Asia-Pacific

Rest of the world (RoW)

Latin America

Middle East & Africa

Russia

Each section of the report offers market data for the various market segments and geographies. It also provides in-depth information on market trends with respect to drivers, restraints, opportunities and technology trends.

 

TABLE OF CONTENTS

1 INTRODUCTION 21

1.1 KEY TAKE-AWAYS 21

1.2 REPORT DESCRIPTION 22

1.3 MARKETS COVERED 23

1.4 STAKEHOLDERS 26

1.5 RESEARCH METHODOLOGY 27

1.5.1 MARKET SIZE 27

1.5.2 MARKET SHARE 27

1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 27

1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28

 

2 EXECUTIVE SUMMARY 29

 

3 MARKET OVERVIEW 33

3.1 INTRODUCTION 34

3.2 MARKET SEGMENTATION 35

3.3 MARKET DYNAMICS 36

3.3.1 DRIVERS 37

3.3.1.1 Increasing demand for diagnostic & image guided procedures influences contrast media sales 37

3.3.1.2 Technological advancements to spur the contrast media market 37

3.3.1.3 Increasing incidence & mortality of cancer & cardiac diseases to boost growth of contrast media 38

3.3.1.4 Growth of medical imaging technology in emerging markets 38

3.3.2 RESTRAINTS 39

3.3.2.1 Major economies undergoing healthcare reforms to affect the sales on contrast media 39

3.3.2.2 Economic slowdown to inhibit growth 40

3.3.3 OPPORTUNITIES 41

3.3.3.1 Growing investment potential in immature emerging markets 41

3.3.3.2 Advent of novel contrast agents combining properties of contrast media & radiopharmaceuticals 41

3.3.4 BURNING ISSUE - TOXICITY 42

3.3.4.1 Nephrogenic systemic fibrosis (NSF) 42

3.3.4.2 Contrast-induced nephrotoxicity (CIN) 43

3.3.5 TECHNOLOGY TRENDS 44

3.3.5.1 N1177 – A revolutionary macrophage labeling agent 44

3.3.5.2 SPAGO Pix – Accurate visualization of tumors with MRI 46

3.3.5.3 CMC-001 – Focused on liver MRI 46

3.4 MARKET SHARE ANALYSIS 47

 

4 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT 50

4.1 INTRODUCTION 51

4.2 BARIUM-BASED CONTRAST MEDIA 55

4.2.1 TECHNICAL OVERVIEW 55

4.2.2 MARKET DYNAMICS 56

4.2.3 MARKET ANALYSIS 56

4.3 IODINATED CONTRAST MEDIA 58

4.3.1 TECHNICAL OVERVIEW 58

4.3.2 MARKET DYNAMICS 58

4.3.3 MARKET ANALYSIS 59

4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR 61

4.3.4.1 Low-osmolar contrast media (LOCM) 61

4.3.4.1.1 Technical overview 61

4.3.4.1.2 Market analysis 63

4.3.4.2 High-osmolar contrast media (HOCM) 64

4.3.4.2.1 Technical overview 64

4.3.4.2.2 Market analysis 65

4.4 GADOLINIUM-BASED CONTRAST MEDIA 66

4.4.1 TECHNICAL OVERVIEW 66

4.4.2 MARKET DYNAMICS 67

4.4.3 MARKET ANALYSIS 67

 

5 GLOBAL CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 69

5.1 INTRODUCTION 70

5.2 ORAL CONTRAST MEDIA 73

5.2.1 TECHNICAL OVERVIEW 73

5.2.2 MARKET DYNAMICS 73

5.2.3 MARKET ANALYSIS 74

5.3 INJECTABLE CONTRAST MEDIA 75

5.3.1 TECHNICAL OVERVIEW 75

5.3.2 MARKET DYNAMICS 76

5.3.3 MARKET ANALYSIS 77

5.3.4 INJECTABLE CONTRAST MEDIA – TYPES 78

5.3.4.1 Intravenous (IV) 78

5.3.4.2 Intra-Arterial (IA) 79

5.4 RECTAL CONTRAST MEDIA 81

5.4.1 TECHNICAL OVERVIEW 81

5.4.2 MARKET DYNAMICS 81

5.4.3 MARKET ANALYSIS 82

5.5 URETHRAL CONTRAST MEDIA 83

5.5.1 TECHNICAL OVERVIEW 83

5.5.2 MARKET DYNAMICS 83

5.5.3 MARKET ANALYSIS 84

 

6 GLOBAL CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE 86

6.1 INTRODUCTION 87

6.2 X-RAY 89

6.2.1 TECHNICAL OVERVIEW 89

6.2.2 MARKET DYNAMICS 90

6.2.3 MARKET ANALYSIS 91

6.3 COMPUTED TOMOGRAPHY (CT) 92

6.3.1 TECHNICAL OVERVIEW 92

6.3.2 MARKET DYNAMICS 93

6.3.3 MARKET ANALYSIS 93

6.4 MAGNETIC RESONANCE IMAGING (MRI) 94

6.4.1 TECHNICAL OVERVIEW 94

6.4.2 MARKET DYNAMICS 95

6.4.3 MARKET ANALYSIS 96

6.5 ULTRASOUND 97

6.5.1 TECHNICAL OVERVIEW 97

6.5.2 MARKET DYNAMICS 97

6.5.3 MARKET ANALYSIS 98

6.6 CATHETERIZATION LABORATORY (CATH LAB) 99

6.6.1 TECHNICAL OVERVIEW 99

6.6.2 MARKET DYNAMICS 100

6.6.3 MARKET ANALYSIS 101

 

7 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION 102

7.1 INTRODUCTION 103

7.2 CARDIOVASCULAR DISORDERS 105

7.2.1 MARKET DYNAMICS 105

7.2.2 MARKET ANALYSIS 106

7.3 NEUROLOGICAL DISORDERS 107

7.3.1 MARKET DYNAMICS 107

7.3.2 MARKET ANALYSIS 107

7.4 RESPIRATORY DISEASES 109

7.4.1 MARKET DYNAMICS 109

7.4.2 MARKET ANALYSIS 109

7.5 GASTROINTESTINAL DISORDERS 111

7.5.1 MARKET DYNAMICS 111

7.5.2 MARKET ANALYSIS 111

7.6 ONCOLOGY 113

7.6.1 MARKET DYNAMICS 113

7.6.2 MARKET ANALYSIS 113

7.7 MUSCULOSKELETAL ANOMALIES 115

7.7.1 MARKET DYNAMICS 115

7.7.2 MARKET ANALYSIS 116

7.8 NEPHROLOGICAL DISORDERS 117

7.8.1 MARKET DYNAMICS 117

7.8.2 MARKET ANALYSIS 117

 

8 GLOBAL CONTRAST MEDIA MARKET, BY APPLICATION 119

8.1 INTRODUCTION 120

8.2 RADIOLOGY 123

8.2.1 TECHNICAL OVERVIEW 123

8.2.2 MARKET DYNAMICS 123

8.2.3 MARKET ANALYSIS 124

8.3 INTERVENTIONAL RADIOLOGY 126

8.3.1 TECHNICAL OVERVIEW 126

8.3.2 MARKET DYNAMICS 126

8.3.3 MARKET ANALYSIS 127

8.4 INTERVENTIONAL CARDIOLOGY 129

8.4.1 TECHNICAL OVERVIEW 129

8.4.2 MARKET DYNAMICS 130

8.4.3 MARKET ANALYSIS 130

 

9 GEOGRAPHIC ANALYSIS 132

9.1 INTRODUCTION 133

9.2 NORTH AMERICA 134

9.3 EUROPE 143

9.4 ASIA-PACIFIC 152

9.5 REST OF THE WORLD (ROW) 161

 

10 COMPETITIVE LANDSCAPE 169

10.1 INTRODUCTION 169

10.2 MERGERS & ACQUISITIONS 172

10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 174

10.4 NEW PRODUCT LAUNCH 178

10.5 EXPANSION 180

10.6 APPROVALS 182

10.7 OTHER DEVELOPMENTS 184

 

11 COMPANY PROFILES 187

11.1 AMAG PHARMACEUTICALS, INC. 195

11.2 BAYER HEALTHCARE PHARMACEUTICALS 199

11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A) 209

11.4 COVIDIEN 213

11.5 CMC CONTRAST AB 220

11.6 DAIICHI SANKYO CO., LTD. 222

11.7 GE HEALTHCARE 228

11.8 GENOVIS AB 235

11.9 GUERBET GROUP 240

11.10 LANTHEUS MEDICAL IMAGING, INC. 247

11.11 NANOPET PHARMA GMBH 254

11.12 NANOSCAN IMAGING, LLC 258

11.13 SANOCHEMIA PHARMAZEUTIKA AG 260

11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB) 267

11.15 SUBHRA PHARMA PRIVATE, LTD 271

11.16 TAEJOON PHARM CO., LTD. 274

11.17 TARGESON, INC. 278

11.18 UNIJULES LIFE SCIENCES, LTD. 283

 

LIST OF TABLES

TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 30

TABLE 2 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 32

TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES 43

TABLE 4 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,

2010 - 2017 ($MILLION) 52

TABLE 5 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 53

TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION) 57

TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 60

TABLE 8 IODINATED CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 - 2017 ($MILLION) 61

TABLE 9 IODINATED-LOCM CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 63

TABLE 10 IODINATED-HOCM CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65

TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 - 2017 ($MILLION) 68

TABLE 12 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 71

TABLE 13 ORAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 75

TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 77

TABLE 15 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 – 2017 ($MILLION) 78

TABLE 16 INTRAVENOUS INJECTABLE CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 79

TABLE 17 INTRA-ARTERIAL INJECTABLE CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 80

TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 82

TABLE 19 URETHRAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 85

TABLE 20 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 88

TABLE 21 X-RAY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 91

TABLE 22 CT CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 94

TABLE 23 MRI CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 96

TABLE 24 ULTRASOUND CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 98

TABLE 25 CATH LAB CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 101

TABLE 26 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 104

TABLE 27 CARDIOVASCULAR DISEASES - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 106

TABLE 28 NEUROLOGICAL DISORDERS - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 108

TABLE 29 RESPIRATORY DISEASES - CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 110

TABLE 30 GASTROINTESTINAL DISORDERS - CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 112

TABLE 31 ONCOLOGY - CONTRAST MEDIA MARKET, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 114

TABLE 32 MUSCULOSKELETAL ANOMALIES – CONTRAST MEDIA MARKET,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 116

TABLE 33 NEPHROLOGICAL DISORDERS - CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 118

TABLE 34 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,

2010 – 2017 ($MILLION) 122

TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 125

TABLE 36 INTERVENTIONAL RADIOLOGY CONTRAST MEDIA MARKET REVENUE,

BY GEOGRAPHY, 2010 – 2017 ($MILLION) 128

TABLE 37 INTERVENTIONAL CARDIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 131

TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,

2010 – 2017 ($MILLION) 133

TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 135

TABLE 40 NORTH AMERICA: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 136

TABLE 41 NORTH AMERICA: IODINATED CONTRAST MEDIA MARKET, BY TYPE, 2010 – 2017 ($MILLION) 137

TABLE 42 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 138

TABLE 43 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 139

TABLE 44 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 140

TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,

BY TYPE, 2010 – 2017 ($MILLION) 141

TABLE 46 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 142

TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 144

TABLE 48 EUROPE: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 145

TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 146

TABLE 50 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 147

TABLE 51 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 148

TABLE 52 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 149

TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 150

TABLE 54 EUROPE: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 151

TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,

2010 – 2017 ($MILLION) 153

TABLE 56 APAC: CONTRAST MEDIA MARKET, BY PRODUCT,

2010 – 2017 ($MILLION) 154

TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 155

TABLE 58 APAC: CONTRAST MEDIA MARKET, BY APPLICATION,

2010 – 2017 ($MILLION) 156

TABLE 59 APAC: CONTRAST MEDIA MARKET, BY INDICATION,

2010 – 2017 ($MILLION) 157

TABLE 60 APAC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 158

TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 159

TABLE 62 APAC: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 160

TABLE 63 ROW: CONTRAST MEDIA MARKET REVENUE, BY REGION,

2010 – 2017 ($MILLION) 161

TABLE 64 ROW: CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,

2010 – 2017 ($MILLION) 162

TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,

2010 – 2017 ($MILLION) 163

TABLE 66 ROW: CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,

2010 – 2017 ($MILLION) 164

TABLE 67 ROW: CONTRAST MEDIA MARKET REVENUE, BY INDICATION,

2010 – 2017 ($MILLION) 165

TABLE 68 ROW: CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 166

TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,

2010 – 2017 ($MILLION) 167

TABLE 70 ROW: CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE,

2010 – 2017 ($MILLION) 168

TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012 172

TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012 174

TABLE 73 NEW PRODUCT LAUNCH, 2010 – 2012 178

TABLE 74 EXPANSION, 2010 – 2012 180

TABLE 75 APPROVALS, 2010 – 2012 182

TABLE 76 OTHER DEVELOPMENTS, 2010 – 2012 184

TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,

2009 – 2011 ($MILLION) 196

TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,

2009 – 2011 ($MILLION) 197

TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 – 2011 ($MILLION) 197

TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 200

TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,

BY SEGMENT, 2009 – 2011 ($MILLION) 201

TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,

BY GEOGRAPHY, 2009 – 2011 ($MILLION) 202

TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 – 2011 ($MILLION) 203

TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 203

TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 - 2011 ($MILLION) 204

TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,

2009 – 2011 ($MILLION) 205

TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 – 2011 ($MILLION) 214

TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 – 2011 ($MILLION) 215

TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,

2009 – 2011 ($MILLION) 216

TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 217

TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,

2009 – 2011 ($BILLION) 223

TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,

2009 – 2011 ($MILLION) 224

TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,

2009 – 2011 ($BILLION) 229

TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,

2009 – 2011 ($BILLION) 229

TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,

2009 – 2011 ($BILLION) 230

TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,

2010 – 2012 ($THOU.S.ND) 236

TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,

2010 – 2012 ($THOU.S.ND) 236

TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,

2010 – 2012 ($MILLION) 241

TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 – 2012 ($MILLION) 242

TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 – 2012 ($MILLION) 243

TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 248

TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 248

TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 249

TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 261

TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2011 ($MILLION) 262

TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 263

TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($THOU.S.ND) 268

 

LIST OF FIGURES

FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 31

FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION 35

FIGURE 3 MARKET DYNAMICS 36

FIGURE 4 GLOBAL CONTRAST MEDIA MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2011 48

FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT 51

FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM) 62

FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM) 64

FIGURE 8 CONTRAST MEDIA MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION 70

FIGURE 9 CONTRAST MEDIA MARKET SEGMENTATION, BY MEDICAL PROCEDURE 87

FIGURE 10 CONTRAST MEDIA MARKET SEGMENTATION, BY INDICATION 103

FIGURE 11 CONTRAST MEDIA MARKET SEGMENTATION, BY APPLICATION 121

FIGURE 12 KEY GROWTH STRATEGIES, 2010 – 2012 169

FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 – 2012 170

FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,

2010 – 2012 171

 

To order this report:

Medical_Imaging Industry: Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...